Evaluation of Clinical Outcomes in Patients Undergoing Dual Vessel Percutaneous Coronary Intervention Using Sirolimus-Eluting Coronary Stent System in India

PRAKASH CHANDWANI, JAYESH PRAJAPATI, SANJAY PORWAL, BHAVESH KHAMBHATI, ASHOK THAKKAR

ABSTRACT
Introduction: Coronary artery disease is the most common catastrophic disease in India. The safety and effectiveness of dual vessel sirolimus-eluting stent (SES) implantation (used as an intervention in CAD) is currently unknown in Indian population. The purpose of this study was to investigate one year clinical outcomes of patients with dual vessel coronary artery disease after implantation of the Supralimus-Core SES, in a “real-world” setting.

Materials and Methods: We evaluated 60 patients between April-2011 and August-2012, who underwent dual vessel percutaneous coronary intervention (PCI) with the Supralimus-Core SES implantation at the same index procedure. Dual vessels were defined as involvement of two major epicardial vessels (right, left anterior descending, circumflex, or left main coronary arteries) or one major epicardial vessel and a branch (≥2.5 mm in diameter) originating from another major epicardial vessel. The primary endpoint was target lesion failure (TLF) defined as the composite of cardiac death, myocardial infarction (MI), and clinically-driven target lesion revascularization (TLR) at one year. Secondary endpoint included combined (definite, probable and possible) stent thrombosis (ST).

Results: A total of 120 lesions were treated in 60 enrolled patients (mean age 56.0±9.2 y; 80.0% male) with average stent length of 23.1±8.5 mm. Among 60 patients, diabetes, hypertension and hypercholesterolemia were present in 15 (25.0%), 22 (36.7%) and 25 (41.7%) patients respectively. Indications for PCI were unstable angina in 30 (50.0%) patients and stable angina in 11 (18.3%) patients. Overall, 40 (33.3%) lesions were classified as complex (American College of Cardiology/American Heart Association type B2/C). The cumulative TLF rate was 5.0% (n=3) at one year. Cardiac death, MI and clinically-driven TLR occurred in 1 (1.7%), 0 (0%) and 2 (3.3%) patients, respectively at one year follow-up. The Kaplan-Meier curve of the freedom from overall events at one year was 95.0%. According to the Academic Research Consortium definition, there were no events of stent thrombosis during one year.

Conclusion: Our study shows that, dual vessel Supralimus-Core SES implantation allows safe and effective treatment with low rates of TLF at one year follow-up in Indian population.

INTRODUCTION
The safety and efficacy of percutaneous transluminal coronary angioplasty (PTCA) has been demonstrated in selected patients with symptomatic coronary artery disease [1,2]. Application of PTCA in patients with multiple vessels or in more extensive coronary artery disease has been limited, and the safety and short- and long-term efficacy are less clear [3–5]. Stent implantation has added an important dimension to percutaneous re-vascularization strategies and has been shown to be an effective rescue device after acute or threatened vessel closure after failed PTCA [6,7].

However, some studies with multivessel disease reported higher restenosis and repeat revascularization rates in patients treated with bare metal stents (BMS) than in those after surgical treatment [8–12]. The introduction of drug-eluting stents (DES) indicating advantage over bare-metal stents in reducing the restenosis incidence and has narrowed the re-intervention gap between percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) surgery in multivessel coronary artery disease (CAD) [8–10,13–16]. Additionally, performing multivessel PCI in a single index procedure has potential economic and social advantages [17].

Here, we present our experience of the use of the Supralimus-Core (Sahajanand Medical Technologies Pvt. Ltd., Surat, India) sirolimus-eluting stent (SES) in patients with dual vessel CAD in an unselected real-world population. No study was especially designed to evaluate the safety and effectiveness of SES in patients with dual vessel disease. The main aim of the study was to conduct a multicenter, observational study including patients with dual vessel CAD, and treated solely with multiple Supralimus-Core SES implantations in a real-world setting, and to report the short (30 days), medium (6 month), and long-term (one year) clinical outcomes.

MATERIALS AND METHODS
Study design and patient population
This was a multi-center, retrospective, observational study conducted at three investigational sites in India; which included 60 patients, treated between April-2011 and August-2012, with dual vessel stenting using the Supralimus-Core SES at the same index procedure. Patients included in this study had either stable or unstable angina or silent ischemia and underwent dual vessel stenting using the Supralimus-Core SES. Dual vessels were defined as involvement of two major epicardial vessels (right, left anterior descending, circumflex, or left main coronary arteries) or one major epicardial vessel and a branch (≥2.5 mm in diameter) originating from another major epicardial vessel. The study was conducted in accordance with the Declaration of Helsinki and study protocol was approved by the Institutional Review Board or Ethics Committee of each participating centres. All patients provided written informed consent prior to their inclusion in the study.

Endpoints of the study and definitions
The primary endpoint of the study was target lesion failure (TLF), defined as cardiac death, myocardial infarction (MI), or clinically-driven target lesion revascularization (TLR) by percutaneous
Characteristics | n = 60 Patients
---|---
Age (mean ± SD, yrs) | 56.0 ± 9.2
Male, n (%) | 48 (80.0%)
Diabetes Mellitus, n (%) | 15 (25.0%)
Hypertension, n (%) | 22 (36.7%)
Smoker, n (%) | 11 (18.3%)
Hypercholesterolemia, n (%) | 25 (41.7%)
Family history of CAD, n (%) | 11 (18.3%)

PCI Indication

Stable Angina, n (%) | 11 (18.3%)
Unstable Angina, n (%) | 30 (50.0%)
Previous MI, n (%) | 8 (13.3%)
Previous PCI, n (%) | 7 (11.7%)
Previous CABG, n (%) | 1 (1.7%)
Previous Stroke, n (%) | 1 (1.7%)

Characteristics | Patients = 60 / Lesions = 120
---|---
Target vessels
Left anterior descending artery, n (%) | 52 (43.3%)
Right coronary artery, n (%) | 31 (25.8%)
Left circumflex artery, n (%) | 37 (30.8%)

Location in vessels
Proximal, n (%) | 48 (40.0%)
Mid, n (%) | 59 (49.2%)
Distal, n (%) | 13 (10.8%)

Coronary vessels combination in dual vessel angioplasty
LAD + LCX, n (%) | 58 (48.3%)
LAD + RCA, n (%) | 46 (38.3%)
RCA + LCX, n (%) | 16 (13.3%)

ACC/AHA Lesion Classification
A, n (%) | 37 (30.8%)
B1, n (%) | 43 (35.8%)
B2, n (%) | 37 (30.8%)
C, n (%) | 3 (2.5%)
Total no. of stent, n | 125
No. of stents per patient, (mean ± SD, mm) | 2.1 ± 0.3
No. of stents per lesion, (mean ± SD, mm) | 1.0 ± 0.2
Average Stent Length, (mean ± SD, mm) | 23.1 ± 8.5
Average Stent Diameter, (mean ± SD, mm) | 3.0 ± 0.3
Total occlusion, n (%) | 8 (6.7%)

Interventional procedure and medical therapy

Coronary angioplasty and the Supralimus-Core SES implantation were performed according to standard practice. Pre-dilatation or direct stenting were performed at the discretion of the operator. Antiplatelet therapy with 300 mg of clopidogrel was administered orally within 24 h before the procedure, unless the patient was already taking clopidogrel. At the start of procedure all patients received intra-arterial bolus of unfractionated heparin (50 to 150 IU/Kg) to achieve an activated clotting time between 250 and 300 sec. Glycoprotein IIb/IIa inhibitors were used at the physician’s discretion. After the procedure aspirin was continued lifelong and clopidogrel administration was recommended for at least 12-months, although standard ischemic therapy was prescribed according to patients conditions at discharge.

Data collection and follow-up

Clinical follow-up was scheduled by telephone communication or office visit at 30 days, 6 month and one year after the index procedure; no patient was lost to follow-up. Follow-up information on all patients was obtained in a prospective manner. The data including demographic information, cardiovascular history, comorbidities, lesion and procedure characteristics, and antithrombotic regimens were collected. These centers provided hard paper copies that were subsequently entered into the database by the data management team. Documentation of adverse events which occurred at other institutions during the follow-up period was obtained from the local physicians and hospital records.

STATISTICAL ANALYSIS

Descriptive statistical analysis was performed by using continuous variables expressed as means with standard deviations and by
using categorical variables presented as percent frequency. The cumulative survival rate free from events was calculated by the Kaplan-Meier analysis. All data were processed using the Statistical Package for Social Sciences, version 15 (SPSS, Chicago, IL, USA).

**RESULTS**

**Patient demographic, lesion and procedural characteristics**

The study included 60 patients (mean age 56.0±9.2 y; 80.0% male) with dual vessel stenting using the Supralimus-Core SES. Patient demographic characteristics including risk factors for coronary artery disease are presented in [Table/Fig-1]. The co-morbidities i.e. diabetes mellitus, hypertension and hypercholesterolemia were present in 15 (25.0%), 22 (38.7%) and 25 (41.7%) patients respectively. Previous MI had occurred in 8 (13.3%) patients and indications for PCI were unstable and stable angina in 30 (50.0%) and 11 (18.3%) patients, respectively. The lesion and procedural characteristics are listed in [Table/Fig-2,3]. Most of the target lesions were located in the left anterior descending artery 52 (43.3%) predominantly in proximal or mid-segments of the treated vessel (89.2%). Overall, 40 (33.3%) lesions were classified as complex (American College of Cardiology/American Heart Association type B2/C), including chronic total occlusions in 8 (6.7%) patients. A total of 125 stents were implanted at index procedure (2.1 stents per patient) with an average diameter and total stent length of 3.0±0.3 mm and 23.1±8.5 mm, respectively.

**Cumulative clinical outcomes**

The 30 day, 6 month and one year clinical outcomes for the overall study population are shown in [Table/Fig-4]. The primary endpoint, a cumulative TLF at one year follow-up, occurred in 3 (5.0%) of 60 patients, consisting of 1 (1.7%) cardiac deaths, 0 (0%) myocardial infarction and 2 (3.3%) clinically-driven TLR. One patient died at 1-year, the results of multivessel stenting in 103 patients and mortality; Q-wave and non-Q-wave MI rates were 1%, 2% and 11%, respectively. Importantly, no patients required emergent CABG at long-term follow-up and event-free survival was 79%. Moussa et al., [29] reported the results of 100 patients undergoing multivessel coronary stenting and during follow up, the mortality, CABG and TVR rates were 4%, 2% and 30%, respectively. Also in our study, no patients required emergent CABG at one year follow-up. These results altogether suggest that multivessel stenting in appropriately selected patients may be a viable therapeutic strategy for patients with multivessel coronary disease.

The Supralimus-Core uses L605 Co-Cr alloy (60 μm strut thickness) as its stent platform which is coated with a biodegradable polymer to deliver sirolimus and, its clinical safety and effectiveness was already demonstrated in various clinical studies [30–34]. In MAXIMUS study, the Supralimus-Core SES has proved its effectiveness by reducing restenosis at 8-months and safety with an acceptable rate of cardiac events at 12-months [30]. Recent, Supralimus-Core optical coherence tomography (OCT) study showed better strut coverage (97.21% at 4-months) with functional endothelium, to avoid in-stent restenosis and to minimize risk of stent thrombosis [33]. Also, S-CORE multi-center registry conducted clearly provides evidence for the safe and effective use of the Supralimus-Core SES in unselected real-world population [34].

In our study, all patients received dual vessel treatment with the Supralimus-Core SES and included a relatively high proportion of complex lesions and the American College of Cardiology/ the American Historical Association (ACC/AHA) types B2 and C lesions, which were less likely to be approached successfully in the randomized trials of multivessel disease. Despite of this, repeat revascularization (3.3%) in the current study at one year was comparable with rates reported in other series of percutaneous management of multivessel disease [35,36]. So, the use of the Supralimus-Core SES in this study did not cause a considerable increase in the rate of repeat revascularization with percutaneous treatment rather than CABG [37].

The present study describes one year clinical outcomes of patients with dual vessel coronary artery disease after implantation of the

---

**Table/Fig-4:** Cumulative clinical outcomes during 30-days, 6-month and 1-year of follow-up (n=60)

<table>
<thead>
<tr>
<th>Event</th>
<th>30-days</th>
<th>6-months</th>
<th>12-months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target lesion failure, n (%)</td>
<td>0 (0%)</td>
<td>1 (1.7%)</td>
<td>3 (5.0%)</td>
</tr>
<tr>
<td>Death, n (%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>1 (1.7%)</td>
</tr>
<tr>
<td>Cardiac Death, n (%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>1 (1.7%)</td>
</tr>
<tr>
<td>Non-cardiac Death, n (%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Myocardial Infarction, n (%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>CABG, n (%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Clinically-driven TLR, n (%)</td>
<td>0 (0%)</td>
<td>1 (1.7%)</td>
<td>2 (3.3%)</td>
</tr>
<tr>
<td>Clinically-driven TVR, n (%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Stent thrombosis, n (%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>

**Table/Fig-5:** Kaplan-Meier curve of cumulative event-free survival over 1-year
Superalimus-Core SES, in a "real-world" setting. In this study, we demonstrated that TLF (cardiac death, MI, and clinically-driven TLR) occurred in 5.0% (n=3) of all patients, with cardiac death occurring in 1.7% (n=1) of patients with dual vessel disease at one year follow-up. Despite the high proportion of patients with high-risk characteristics and complex lesions, there were no events of stent thrombosis during one year. Kaplan-Meier analysis in the current study suggested that 95.0% of patients did not need subsequent hospitalization for heart disease during the first year of follow-up study.

**STUDY LIMITATIONS**

There are several limitations to our study. First, this is a retrospective, observational study rather than a prospective randomized clinical trial designed to assess the safety and efficacy of stents in patients with dual vessel disease. Second, there are data of selected patients who underwent a successful procedure with only Superalimus-Core SES at same index procedure. Third, longer term (>1-year) follow-up in a larger cohort of patients is necessary in order to assess the true rate of restenosis.

**CONCLUSION**

Our study shows that, dual vessel Superalimus-Core SES implantation allows safe and effective treatment with low rates of TLF at one year follow-up in Indian population. Despite the complex lesion morphology, there were no events of stent thrombosis during one year follow-up. Longer follow-up in a large population is clearly required.

**DISCLOSURE**

Dr. Ashok Thakkar and Mr. Bhavesh Kambah are the employees of Sahajanand Medical Technologies Pvt. Ltd. and have provided detailed assistance in literature search and manuscript writing. Other authors declare that they have no conflict of interest. No grant was received from Sahajanand Medical Technologies Pvt. Ltd. for the study.

**REFERENCES**


PARTICULARS OF CONTRIBUTORS:
1. Director, Department of Cardiology, Heart and General Hospital, 7, Vivekanand Marg, C-Scheme, Jaipur, India.
2. Senior Interventional Cardiologist, Department of Cardiology, Apollo Hospitals International Limited, Gandhinagar, Gujarat, India.
3. Associate Professor, Department of Cardiology, KLEs Dr. Prabhakar Kore Hospital & Medical Research Centre, Belgaum, Karnataka, India.
4. Senior Clinical Research Associate, Department of Clinical Trials, Sahajanand Medical Technologies Pvt. Ltd., Surat, Gujarat, India.
5. Senior Manager, Clinical Research and Medical Writing, Department of Clinical Trials, Sahajanand Medical Technologies Pvt. Ltd., Surat, Gujarat, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:
Dr. Prakash Chandwani,
MD, DM (Cardiology), Heart and General Hospital, 7, Vivekanand Marg, C-Scheme, Jaipur- 302001, Rajasthan, India.
E-mail : chandwanipc@gmail.com

FINANCIAL OR OTHER COMPETING INTERESTS: None.

Date of Submission: Aug 04, 2014
Date of Peer Review: Nov 23, 2014
Date of Acceptance: Nov 26, 2014
Date of Publishing: Feb 01, 2015